Cerimon Pharmaceuticals
South San Francisco
About Cerimon Pharmaceuticals
Cerimon Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for autoimmune diseases, inflammation, and pains in the United States and Europe. It develops Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, including pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. Cerimon Pharmaceuticals, Inc. was founded in 2004 and is headquartered in South San Francisco, California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $72.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2010)
- Website: cerimon.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/cerimon-pharmaceuticals-920698 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.